A phase 2 randomized study of Osimertinib versus Osimertinib plus Chemotherapy for patients with Metastatic EGFR-Mutant Lung Cancers that have detectable EGFR Mutant cfDNA in plasma after initiation of Osimertinib

Description

This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to osimertinib could possibly add to the anticancer effects of the usual treatment and help stop cancer from growing or spreading.

Resources and Links

Phone Number: 1-877-MDA-6789

clinicaltrials.gov NCT No: NCT04410796 Opens a new window